1
|
Packer S, Pichon B, Thompson S, Neale J, Njoroge J, Kwiatkowska RM, Oliver I, Telfer M, Doumith M, Buunaaisie C, Heinsbroek E, Hopewell-Kelly N, Desai M, Hope V, Williams OM, Kearns A, Hickman M, Gobin M. Clonal expansion of community-associated meticillin-resistant Staphylococcus aureus (MRSA) in people who inject drugs (PWID): prevalence, risk factors and molecular epidemiology, Bristol, United Kingdom, 2012 to 2017. ACTA ACUST UNITED AC 2020; 24. [PMID: 30940316 PMCID: PMC6446509 DOI: 10.2807/1560-7917.es.2019.24.13.1800124] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Background: In 2015, Bristol (South West England) experienced a large increase in cases of meticillin-resistant Staphylococcus aureus (MRSA) infection in people who inject drugs (PWID). Aim: We aimed to characterise and estimate the prevalence of MRSA colonisation among PWID in Bristol and test evidence of a clonal outbreak. Methods: PWID recruited through an unlinked-anonymous community survey during 2016 completed behavioural questionnaires and were screened for MRSA. Univariable logistic regression examined associations with MRSA colonisation. Whole-genome sequencing used lineage-matched MRSA isolates, comparing PWID (screening and retrospective bacteraemia samples from 2012-2017) with non-PWID (Bristol screening) in Bristol and national reference laboratory database samples. Results: The MRSA colonisation prevalence was 8.7% (13/149) and was associated with frequently injecting in public places (odds ratio (OR): 5.5; 95% confidence interval (CI):1.34–22.70), recent healthcare contact (OR: 4.3; 95% CI: 1.34–13.80) and injecting in groups of three or more (OR: 15.8; 95% CI: 2.51–99.28). People reporting any one of: injecting in public places, injection site skin and soft tissue infection or hospital contact accounted for 12/13 MRSA positive cases (sensitivity 92.3%; specificity 51.5%). Phylogenetic analysis identified a dominant clade associated with infection and colonisation among PWID in Bristol belonging to ST5-SCCmecIVg. Conclusions: MRSA colonisation in Bristol PWID is substantially elevated compared with general population estimates and there is evidence of clonal expansion, community-based transmission and increased infection risk related to the colonising strain. Targeted interventions, including community screening and suppression therapy, education and basic infection control are needed to reduce MRSA infections in PWID.
Collapse
Affiliation(s)
- Simon Packer
- Field Epidemiology Service, Public Health England, Bristol, United Kingdom
| | - Bruno Pichon
- Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, National Infection Service, Public Health England, London, United Kingdom
| | - Stephen Thompson
- Public health laboratory Bristol, Public Health England, Bristol, United Kingdom
| | - Jane Neale
- Bristol Drugs Project, Bristol, United Kingdom
| | - Jacquelyn Njoroge
- Blood Borne Virus Section, HIV & STI Department, National Infection Service, Public Health England, London, United Kingdom
| | - Rachel M Kwiatkowska
- NIHR Health Protection Research Unit in Evaluation of Interventions at University of Bristol, Bristol, United Kingdom.,Field Epidemiology Service, Public Health England, Bristol, United Kingdom
| | - Isabel Oliver
- NIHR Health Protection Research Unit in Evaluation of Interventions at University of Bristol, Bristol, United Kingdom.,Field Epidemiology Service, Public Health England, Bristol, United Kingdom
| | | | - Michel Doumith
- King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.,Infectious Diseases Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.,Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, National Infection Service, Public Health England, London, United Kingdom
| | | | - Ellen Heinsbroek
- Blood Borne Virus Section, HIV & STI Department, National Infection Service, Public Health England, London, United Kingdom
| | | | - Monica Desai
- Blood Borne Virus Section, HIV & STI Department, National Infection Service, Public Health England, London, United Kingdom
| | - Vivian Hope
- Public Health Institute, Liverpool John Moores University, Liverpool, United Kingdom.,Blood Borne Virus Section, HIV & STI Department, National Infection Service, Public Health England, London, United Kingdom
| | - Owen Martin Williams
- Public health laboratory Bristol, Public Health England, Bristol, United Kingdom
| | - Angela Kearns
- Authors contributed equally to the work and share last authorship.,Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, National Infection Service, Public Health England, London, United Kingdom
| | - Mathew Hickman
- Authors contributed equally to the work and share last authorship.,School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom.,NIHR Health Protection Research Unit in Evaluation of Interventions at University of Bristol, Bristol, United Kingdom
| | - Maya Gobin
- Authors contributed equally to the work and share last authorship.,Field Epidemiology Service, Public Health England, Bristol, United Kingdom
| |
Collapse
|
2
|
Are there missed opportunities for vaccinating against hepatitis B among people who inject drugs in the UK? Epidemiol Infect 2020; 147:e244. [PMID: 31364574 PMCID: PMC6805756 DOI: 10.1017/s0950268819001353] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Sustaining the impact of hepatitis B virus (HBV) vaccination on incidence and prevalence of HBV infection requires increasing and maintaining the uptake of vaccine among those at risk. In recent years, the level of vaccine uptake among people who inject drugs (PWID) in the UK has levelled-off. Data (2015–2016) from the national unlinked-anonymous monitoring survey of PWID, an annual survey that collects data from PWID across England, Wales and Northern Ireland, were used to examine HBV vaccine uptake. Data from participants who had injected drugs during the previous year were used to investigate sources of hepatitis B vaccine doses as well as factors associated with vaccine uptake. Among the 3175 anti-HBc-negative participants, 3138 (99%) reported their vaccination status; 23% (714) reported no vaccine uptake. Among those not vaccinated, 447 (63%) reported being sexually active and 116 (16%) reported sharing needles and syringes. Majority of those not vaccinated reported accessing services in the previous year that could have provided hepatitis B vaccine doses. These missed opportunities for vaccinating of PWID indicate a need for additional targeted interventions.
Collapse
|
3
|
Stevens A. 'Being human' and the 'moral sidestep' in drug policy: Explaining government inaction on opioid-related deaths in the UK. Addict Behav 2019; 90:444-450. [PMID: 30220439 DOI: 10.1016/j.addbeh.2018.08.036] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2018] [Revised: 08/29/2018] [Accepted: 08/29/2018] [Indexed: 11/27/2022]
Abstract
BACKGROUND With drug-related deaths at record levels in the UK, the government faces two potential sources of pressure to implement more effective policies. One source is the individuals and families who are most likely to suffer from such deaths; i.e. working class people living in de-industrialised areas. The other source is experts who argue for different policy on the basis of research evidences. AIM This article aims to explain why, in the face of these two potential sources of pressure, the UK government has not implemented effective measures to reduce deaths. METHOD The article uses critical realist discourse analysis of official documents and ministerial speeches on recent British drug policy (2016-2018). It explore this discourse through the theoretical lens of Archer's (2000) ideas on 'being human' and by drawing on Sayer's (2005) work on the 'moral significance of class'. RESULTS Members of economically 'residual' groups (including working class people who use heroin) are excluded from articulating their interests in 'late welfare capitalism' in a project of depersonalising 'class contempt' through which politicians cast the people most likely to die as passive, 'vulnerable' 'abjects'. Conservative politicians dismiss 'evidence-based' ideas on the reduction of drug-related death through a 'moral sidestep'. They defend policy on the basis of its relevance to conservative moral principles, not effectiveness. This is consistent with the broader moral and political pursuit of partial state shrinkage which Conservative politicians and the social groups they represent have pursued since the 1970s.
Collapse
Affiliation(s)
- Alex Stevens
- School of Social Policy, Sociology and Social Research, University of Kent, Chatham Maritime, ME4 4AG, United Kingdom.
| |
Collapse
|
4
|
Hope VD, Harris RJ, Vickerman P, Platt L, Shute J, Cullen KJ, Ijaz S, Mandal S, Ncube F, Desai M, Parry JV. A comparison of two biological markers of recent hepatitis C virus (HCV) infection: implications for the monitoring of interventions and strategies to reduce HCV transmission among people who inject drugs. Euro Surveill 2018; 23:1700635. [PMID: 30482265 PMCID: PMC6341939 DOI: 10.2807/1560-7917.es.2018.23.47.1700635] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
BackgroundMonitoring hepatitis C virus (HCV) incidence is important for assessing intervention impact. Longitudinal studies of people who inject drugs (PWID), using repeated biological tests, are costly; alternatively, incidence can be estimated using biological markers of recent infection in cross-sectional studies.AimWe aimed to compare incidence estimates obtained from two different biological markers of recent infection in a cross-sectional study to inform monitoring approaches for HCV elimination strategies.MethodSamples from an unlinked anonymous bio-behavioural survey of PWID were tested for two recent infection markers: HCV RNA with anti-HCV negative ('RNA') and low-avidity anti-HCV with HCV RNA present ('avidity'). These two markers were used separately and in combination to estimate HCV incidence.ResultsBetween 2011 and 2013, 2,816 anti-HIV-negative PWID (25% female) who had injected during the preceding year were either HCV-negative or had one of the two markers of recent infection: 57 (2.0%) had the RNA marker and 90 (3.2%) the avidity marker. The two markers had similar distributions of risk and demographic factors. Pooled estimated incidence was 12.3 per 100 person-years (pyrs) (95% credible interval: 8.8-17.0) and not significantly different to avidity-only (p = 0.865) and RNA-only (p = 0.691) estimates. However, the RNA marker is limited by its short duration before anti-HCV seroconversion and the avidity marker by uncertainty around its duration.ConclusionBoth markers have utility in monitoring HCV incidence among PWID. When HCV transmission is high, one marker may provide an accurate estimate of incidence; when it is low or decreasing, a combination may be required.
Collapse
Affiliation(s)
- Vivian D Hope
- Public Health Institute, Liverpool John Moores University, Liverpool, United Kingdom,National Infection Service, Public Health England, London, United Kingdom
| | - Ross J Harris
- National Infection Service, Public Health England, London, United Kingdom
| | | | - Lucy Platt
- Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Justin Shute
- National Infection Service, Public Health England, London, United Kingdom
| | - Katelyn J Cullen
- National Infection Service, Public Health England, London, United Kingdom
| | - Samreen Ijaz
- National Infection Service, Public Health England, London, United Kingdom ,The National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Blood Borne and Sexually Transmitted Infections at University College London, London, United Kingdom
| | - Sema Mandal
- National Infection Service, Public Health England, London, United Kingdom ,The National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Blood Borne and Sexually Transmitted Infections at University College London, London, United Kingdom
| | - Fortune Ncube
- National Infection Service, Public Health England, London, United Kingdom
| | - Monica Desai
- National Infection Service, Public Health England, London, United Kingdom
| | - John V Parry
- National Infection Service, Public Health England, London, United Kingdom ,Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom
| |
Collapse
|
5
|
Hope VD, Iversen J, Cullen KJ, Parry JV, Maher L, Nucbe F. Injection into the jugular vein among people who inject drugs in the United Kingdom: Prevalence, associated factors and harms. THE INTERNATIONAL JOURNAL OF DRUG POLICY 2017; 46:28-33. [DOI: 10.1016/j.drugpo.2017.05.005] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2016] [Revised: 04/07/2017] [Accepted: 05/02/2017] [Indexed: 10/19/2022]
|
6
|
O'Halloran C, Cullen K, Njoroge J, Jessop L, Smith J, Hope V, Ncube F. The extent of and factors associated with self-reported overdose and self-reported receipt of naloxone among people who inject drugs (PWID) in England, Wales and Northern Ireland. THE INTERNATIONAL JOURNAL OF DRUG POLICY 2017; 46:34-40. [PMID: 28586701 DOI: 10.1016/j.drugpo.2017.05.017] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Revised: 03/11/2017] [Accepted: 05/03/2017] [Indexed: 11/15/2022]
Abstract
BACKGROUND Overdose is a major cause of death among PWID, and for opioid overdoses naloxone administration can reduce harm. However, globally there is limited national level data on the extent of non-fatal overdose and naloxone uptake. The first national level data on the extent of self-reported overdose and self-reported receipt of naloxone among UK PWID, providing a baseline to monitor the impact of the recent policy change regarding naloxone availability, is presented. METHODS Data on self-reported overdose and receipt of naloxone during the preceding year for 2013-2014 from a national survey of PWID was analysed. Participants who reported injecting during the preceding year were included. RESULTS Participants (3850) were predominantly male (75%); mean age was 36 years. The most commonly injected drugs were: heroin (91%), crack (45%) and amphetamine (29%). 15% (591) reported overdosing during the preceding year. There were no differences in the proportion reporting overdose by age or gender, but overdose was more common among those who: injected multiple drugs; recently ceased addiction treatment; injected with used needles/syringes; ever had transactional sex; had used a sexual health clinic or emergency department and lived in Wales or Northern Ireland. Among those reporting an overdose during the preceding year, a third reported two to four overdoses and 7.5% five or more overdoses; half reported receiving naloxone. Those reporting naloxone receipt in the preceding year were more likely to: live in Wales or Northern Ireland; ever received used needles/syringes; ever been imprisoned; and less likely to have injected two drug types. CONCLUSION These data provide a baseline for monitoring the impact of the 2015 UK policy change to improve take-home naloxone access. Interventions tackling overdose should promote naloxone awareness and access, and target those who; are poly-drug injectors, have ceased treatment, share needles/syringes and whose drug use links to sexual activity.
Collapse
Affiliation(s)
- Charlotte O'Halloran
- HIV & STI Department, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK.
| | - Katelyn Cullen
- HIV & STI Department, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK
| | - Jaquelyn Njoroge
- HIV & STI Department, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK
| | - Lucy Jessop
- Public Health Agency, Health Protection Service, 12-22 Linenhall Street, Belfast BT2 8BS, Northern Ireland, UK
| | - Josie Smith
- Public Health Wales, Temple of Peace & Health, Cathays Park, Cardiff CF10 3NW, UK
| | - Vivian Hope
- HIV & STI Department, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK
| | - Fortune Ncube
- HIV & STI Department, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK
| |
Collapse
|
7
|
Hope VD, Cullen KJ, Smith J, Jessop L, Parry J, Ncube F. Is the recent emergence of mephedrone injecting in the United Kingdom associated with elevated risk behaviours and blood borne virus infection? ACTA ACUST UNITED AC 2017; 21:30225. [PMID: 27195614 DOI: 10.2807/1560-7917.es.2016.21.19.30225] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2015] [Accepted: 01/08/2016] [Indexed: 12/21/2022]
Abstract
The recent, and rapid, emergence of injection of the short-acting stimulant mephedrone (4-methylmethcathione) has resulted in concerns about increased infection risks among people who inject drugs (PWID). Data from the bio-behavioural surveillance of PWID in the United Kingdom were analysed to examine the impact of mephedrone injection on infections among PWID. During the year preceding the survey, 8.0% of PWID (163/2,047) had injected mephedrone. In multivariable analyses, those injecting mephedrone were younger, less likely to have injected opiates, and more likely to have injected cocaine or amphetamines, used needle/syringe programmes or sexual health clinics, been recruited in Wales and Northern Ireland or shared needles/syringes. There were no differences in sexual risks. Those injecting mephedrone more often had hepatitis C antibodies (adjusted odds ratio (AOR) = 1.51; 95% confidence interval (CI): 1.08-2.12), human immunodeficiency virus (AOR = 5.43; 95% CI: 1.90-15.5) and overdosed (AOR = 1.70; 95% CI: 1.12-2.57). There were no differences in the frequency of injecting site infections or prevalence of hepatitis B. The elevated levels of risk and infections are a concern considering its recent emergence. Mephedrone injection may currently be focused among higher-risk or more vulnerable groups. Targeted responses are needed to prevent an increase in harm.
Collapse
Affiliation(s)
- Vivian D Hope
- Centre for Infectious Disease Surveillance and Control, Public Health England, London, United Kingdom
| | | | | | | | | | | |
Collapse
|
8
|
Hope VD, Harris R, McVeigh J, Cullen KJ, Smith J, Parry JV, DeAngelis D, Ncube F. Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and Performance Enhancing Drugs in England and Wales: Results From Cross-Sectional Prevalence Surveys, 1992-2013. J Acquir Immune Defic Syndr 2016; 71:331-7. [PMID: 26361173 PMCID: PMC4770362 DOI: 10.1097/qai.0000000000000835] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2015] [Accepted: 08/04/2015] [Indexed: 01/07/2023]
Abstract
BACKGROUND Infection risks among people who inject drugs (PWID) are widely recognized, but few studies have focused on image and performance enhancing drugs (IPEDs). Globally, concern about IPED injection has increased and, in the United Kingdom, IPED injectors have become the largest group using Needle and Syringe Programmes. Blood-borne virus prevalence trends among IPED injectors are explored. METHOD Data from 2 surveys of IPED injectors (2010-2011; 2012-2013) and the national bio-behavioral surveillance system for PWID (1992-1997; 1998-2003; 2004-2009) were merged. Psychoactive drug injectors and women were excluded. Logistic regression analyses explored temporal changes. RESULTS Between 1992 and 2009, median age increased from 25 to 29 years (N = 1296), years injecting from 2 to 4. There were 53 men who had sex with men (MSM). Overall, 0.93% had HIV, 4.4% ever had hepatitis B (HBV), and 3.9% hepatitis C (HCV, from 1998, N = 1083). In multivariable analyses, HIV increased in 2004-2009 [adjusted odds ratio (AOR) = 10 (95% confidence interval (CI): 0.94 to 106) vs. 1992-2003], and remained elevated (AOR = 4.12, 95% CI: 0.31 to 54, 2012-2013); HBV also increased in 2004-2009 (AOR = 3.98, 95% CI: 1.59 to 9.97). HCV prevalence increase was only borderline significant (AOR = 2.47, 95% CI: 0.90 to 6.77, 2010-2011). HIV and HBV were associated with MSM and HCV with sharing needles/syringes. Uptake of diagnostic testing for HIV and HCV, and HBV vaccination increased (to 43%, 32% and 44% respectively). Condom use was consistently poor; needle/syringe sharing occurred. CONCLUSION Blood-borne virus prevalences among IPED injectors have increased and for HIV, is now similar to that among psychoactive drug injectors. Targeted interventions to reduce risks are indicated.
Collapse
Affiliation(s)
- Vivian D. Hope
- National Infection Service, Public Health England, London, United Kingdom
- Centre for Research on Drugs and Health Behaviour, Department of Social and Environmental Health Research, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Ross Harris
- National Infection Service, Public Health England, London, United Kingdom
| | - Jim McVeigh
- Centre for Public Health, Liverpool John Moores University, Liverpool, United Kingdom
| | - Katelyn J. Cullen
- Centre for Research on Drugs and Health Behaviour, Department of Social and Environmental Health Research, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Josie Smith
- Public Health Wales, Temple of Peace and Health, Cardiff, United Kingdom; and
| | - John V. Parry
- National Infection Service, Public Health England, London, United Kingdom
- Centre for Research on Drugs and Health Behaviour, Department of Social and Environmental Health Research, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Daniela DeAngelis
- National Infection Service, Public Health England, London, United Kingdom
- MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, United Kingdom
| | - Fortune Ncube
- Centre for Research on Drugs and Health Behaviour, Department of Social and Environmental Health Research, London School of Hygiene and Tropical Medicine, London, United Kingdom
| |
Collapse
|
9
|
Hope VD, Scott J, Cullen KJ, Parry JV, Ncube F, Hickman M. Going into the groin: Injection into the femoral vein among people who inject drugs in three urban areas of England. Drug Alcohol Depend 2015; 152:239-45. [PMID: 25913887 DOI: 10.1016/j.drugalcdep.2015.03.029] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2014] [Revised: 03/27/2015] [Accepted: 03/28/2015] [Indexed: 11/26/2022]
Abstract
BACKGROUND There have been increasing concerns about injection into the femoral vein - groin injecting - among people who inject drugs in a number of countries, though most studies have been small. The extent, reasons and harms associated with groin injecting are examined. METHOD Participants were recruited using respondent driven sampling (2006-2009). Weighted data was examined using bivariate analyses and logistic regression. RESULTS The mean age was 32 years; 25% were women (N=855). During the preceding 28 days, 94% had injected heroin and 13% shared needles/syringes. Overall, 53% reported ever groin injecting, with 9.8% first doing so at the same age as starting to inject. Common reasons given for groin injecting included: "Can't get a vein elsewhere" (68%); "It is discreet" (18%); and "It is quicker" (14%). During the preceding 28 days, 41% had groin injected, for 77% this was the only body area used (for these "It is discreet" was more frequently given as a reason). In the multivariable analysis, groin injection was associated with: swabbing injection sites; saving filters for reuse; and receiving opiate substitution therapy. It was less common among those injecting into two body areas, and when other people (rather than services) were the main source of needles. Groin injection was more common among those with hepatitis C and reporting ever having deep vein thrombosis or septicaemia. CONCLUSIONS Groin injection was common, often due to poor vascular access, but for some it was out of choice. Interventions are required to reduce injecting risk and this practice.
Collapse
Affiliation(s)
- V D Hope
- Centre for Infectious Disease Surveillance and Control, Public Health England, London, UK; Centre for Research on Drugs & Health Behaviour, London School of Hygiene & Tropical Medicine, London, UK.
| | - J Scott
- Department of Pharmacy & Pharmacology, University of Bath, Bath, UK
| | - K J Cullen
- Centre for Infectious Disease Surveillance and Control, Public Health England, London, UK
| | - J V Parry
- Microbiology Services, Public Health England, London, UK; Centre for Research on Drugs & Health Behaviour, London School of Hygiene & Tropical Medicine, London, UK
| | - F Ncube
- Centre for Infectious Disease Surveillance and Control, Public Health England, London, UK
| | - M Hickman
- School of Social and Community Medicine, University of Bristol, Bristol, UK
| |
Collapse
|
10
|
Abstract
In this article, I compare and contrast policymaking processes in Canada and England and Wales between 1997 and the present day to provide insight into why the Canadian government approved the opening of a downtown Vancouver drug consumption room (DCR) named InSite in 2003, and why the British government has not yet done so. I also shed new light on why, since 2003, subsequent DCRs have not been opened in either Canada or England and Wales. I briefly consider future prospects for DCRs in both places. To accomplish this, I draw on Kingdon’s “Multiple Streams Theory,” which suggests that national government decision makers such as politicians are most likely to enact policy changes when there is an alignment of problems, policy options, and political circumstances. I argue that such conditions existed in Canada but not England and Wales, which helps explain why the Canadian government approved the opening of a DCR but the British government did not. I draw on primary data from national, provincial, and municipal government documents and national and local newspaper articles in both jurisdictions to make my argument, along with secondary data from published literature. In the process, I highlight the strengths and weaknesses of Kingdon’s (1984) work for understanding policy development in the highly controversial area of illicit drug use.
Collapse
Affiliation(s)
- Steven Hayle
- Department of Sociology, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
11
|
Hope V, Cullen K, Croxford S, Parry J, Ncube F. Factors associated with the use of cleaned needles and syringes among people who inject drugs in the UK: Who should we target to minimise the risks? THE INTERNATIONAL JOURNAL OF DRUG POLICY 2014; 25:924-7. [DOI: 10.1016/j.drugpo.2014.02.008] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2013] [Revised: 02/15/2014] [Accepted: 02/18/2014] [Indexed: 11/17/2022]
|
12
|
Factors associated with recently acquired hepatitis C virus infection in people who inject drugs in England, Wales and Northern Ireland: new findings from an unlinked anonymous monitoring survey. Epidemiol Infect 2014; 143:1398-407. [PMID: 25119383 DOI: 10.1017/s0950268814002040] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Monitoring infections and risk in people who inject drugs (PWID) is important for informing public health responses. In 2011, a novel hepatitis C antibody (anti-HCV) avidity-testing algorithm to identify samples compatible with recent primary infection was introduced into a national surveillance survey. PWID are recruited annually, through >60 needle-and-syringe programmes and prescribing services. Of the 980 individuals that could have been at risk of HCV infection, there were 20 (2%) samples that were compatible with recent primary infection. These were more common among: those imprisoned ⩾5 times [8/213; adjusted odds ratio (aOR) 8·7, 95% confidence interval (CI) 2·04-37·03]; women (8/230; aOR 3·8, 95% CI 1·41-10·38); and those ever-infected with hepatitis B (5/56; aOR 6·25, 95% CI 2·12-18·43). This study is the first to apply this algorithm and to examine the risk factors associated with recently acquired HCV infection in a national sample of PWID in the UK. These findings highlight underlying risks and suggest targeted interventions are needed.
Collapse
|
13
|
Hope VD, Harris RJ, De Angelis D, Croxford S, Marongiu A, Parry JV, Ncube F. Two decades of successes and failures in controlling the transmission of HIV through injecting drug use in England and Wales, 1990 to 2011. ACTA ACUST UNITED AC 2014; 19. [PMID: 24739984 DOI: 10.2807/1560-7917.es2014.19.14.20762] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Responses to injecting drug use have changed focus over the last 20 years. Prevalence and incidence of human immunodeficiency virus (HIV) among people who inject drugs (PWID) in England and Wales were examined in relation to these changes. A voluntary unlinked-anonymous surveillance study obtained a biological sample and questionnaire data from PWID through annual surveys since 1990. Prevalence and incidence trends were estimated via generalised linear models, and compared with a policy time-line. Overall HIV prevalence among 38,539 participations was 1.15%. Prevalence was highest among those who started injecting before 1985; throughout the 1990s, prevalence fell in this group and was stable among those who started injecting later. Prevalence was higher in 2005 than 2000 (odds ratio: 3.56 (95% confidence interval (CI) 1.40–9.03) in London, 3.40 (95% CI 2.31–5.02) elsewhere). Estimated HIV incidence peaked twice, around 1983 and 2005. HIV was an important focus of policy concerning PWID from 1984 until 1998. This focus shifted at a time when drug use and risk were changing. The increased incidence in 2005 cannot be ascribed to the policy changes, but these appeared to be temporally aligned. Policy related to PWID should be continually reviewed to ensure rapid responses to increased risk.
Collapse
Affiliation(s)
- V D Hope
- Centre for Infectious Disease Surveillance and Control, Public Health England, London, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
14
|
Injection site infections and injuries in men who inject image- and performance-enhancing drugs: prevalence, risks factors, and healthcare seeking. Epidemiol Infect 2014; 143:132-40. [PMID: 24713416 DOI: 10.1017/s0950268814000727] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
People who inject drugs are vulnerable to infections and injuries at injection sites, but these have rarely been studied in those injecting image- and performance-enhancing drugs (IPEDs). This study examined the factors associated with reported symptoms of injection site infections and injuries in IPED injectors. Of the 366 male IPED injectors surveyed, 42% reported ever having redness, swelling and tenderness (36% in the preceding year), and 6·8% had ever had an abscess or open wound at an injection site. Having these symptoms was associated with a range of factors related to drug use and healthcare utilization. One sixth (17%) of those reporting redness, tenderness and swelling had ever sought treatment, as had the majority (76%) of those reporting an abscess, sore or open wound. Most common sources of advice were emergency clinics and General Practitioners. Interventions are needed to support access to appropriate injecting equipment and provide targeted harm reduction advice.
Collapse
|
15
|
Abdul-Quader AS, Feelemyer J, Modi S, Stein ES, Briceno A, Semaan S, Horvath T, Kennedy GE, Des Jarlais DC. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review. AIDS Behav 2013; 17:2878-92. [PMID: 23975473 PMCID: PMC6509353 DOI: 10.1007/s10461-013-0593-y] [Citation(s) in RCA: 153] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Needle-syringe programs (NSP) have been effective in reducing HIV and hepatitis C (HCV) infection among people who inject drugs (PWID). Achieving sustainable reductions in these blood-borne infections requires addressing structural factors so PWID can legally access NSP services. Systematic literature searches collected information on NSP coverage and changes in HIV or HCV infection prevalence or incidence at the population level. Included studies had to document biomarkers (HIV or HCV) coupled with structural-level NSP, defined by a minimum 50 % coverage of PWID and distribution of 10 or more needles/syringe per PWID per year. Fifteen studies reported structural-level NSP and changes in HIV or HCV infection prevalence/incidence. Nine reported decreases in HIV prevalence, six in HCV infection prevalence, and three reported decreases in HIV incidence. The results support NSP as a structural-level intervention to reduce population-level infection and implementation of NSP for prevention and treatment of HIV and HCV infection.
Collapse
Affiliation(s)
- Abu S Abdul-Quader
- Center for Global Health, Division of Global HIV/AIDS, Epidemiology and Strategic Information Branch, Centers for Disease Control and Prevention, CORP Bldg 1 Rm 2308.02, MS E30, Atlanta, GA, 30329-1902, USA,
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Hope VD, McVeigh J, Marongiu A, Evans-Brown M, Smith J, Kimergård A, Croxford S, Beynon CM, Parry JV, Bellis MA, Ncube F. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study. BMJ Open 2013; 3:e003207. [PMID: 24030866 PMCID: PMC3773656 DOI: 10.1136/bmjopen-2013-003207] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
OBJECTIVE To describe drug use, sexual risks and the prevalence of blood-borne viral infections among men who inject image and performance enhancing drugs (IPEDs). DESIGN A voluntary unlinked-anonymous cross-sectional biobehavioural survey. SETTING 19 needle and syringe programmes across England and Wales. PARTICIPANTS 395 men who had injected IPEDs. RESULTS Of the participants (median age 28 years), 36% had used IPEDs for <5 years. Anabolic steroids (86%), growth hormone (32%) and human chorionic gonadotropin (16%) were most frequently injected, with 88% injecting intramuscularly and 39% subcutaneously. Two-thirds also used IPEDs orally. Recent psychoactive drug use was common (46% cocaine, 12% amphetamine), 5% had ever injected a psychoactive drug and 9% had shared injecting equipment. 'Viagra/Cialis' was used by 7%, with 89% reporting anal/vaginal sex in the preceding year (20% had 5+ female-partners, 3% male-partners) and 13% always using condoms. Overall, 1.5% had HIV, 9% had antibodies to the hepatitis B core antigen (anti-HBc) and 5% to hepatitis C (anti-HCV). In multivariate analysis, having HIV was associated with: seeking advice from a sexual health clinic; having had an injection site abscess/wound; and having male partners. After excluding those reporting male partners or injecting psychoactive drugs, 0.8% had HIV, 8% anti-HBc and 5% anti-HCV. Only 23% reported uptake of the hepatitis B vaccine, and diagnostic testing uptake was poor (31% for HIV, 22% for hepatitis C). CONCLUSIONS Previous prevalence studies had not found HIV among IPED injectors. HIV prevalence in this, the largest study of blood-borne viruses among IPED injectors, was similar to that among injectors of psychoactive drugs. Findings indicate a need for targeted interventions.
Collapse
|
17
|
Palmateer NE, Hope VD, Roy K, Marongiu A, White JM, Grant KA, Ramsay CN, Goldberg DJ, Ncube F. Infections with spore-forming bacteria in persons who inject drugs, 2000-2009. Emerg Infect Dis 2013; 19:29-34. [PMID: 23260795 PMCID: PMC3557973 DOI: 10.3201/eid1901.120044] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Clusters of almost 300 cases in time and location might be the result of contamination of specific heroin batches. Since 2000 in the United Kingdom, infections caused by spore-forming bacteria have been associated with increasing illness and death among persons who inject drugs (PWID). To assess temporal and geographic trends in these illnesses (botulism, tetanus, Clostridium novyi infection, and anthrax), we compared rates across England and Scotland for 2000–2009. Overall, 295 infections were reported: 1.45 per 1,000 PWID in England and 4.01 per 1,000 PWID in Scotland. The higher rate in Scotland was mainly attributable to C. novyi infection and anthrax; rates of botulism and tetanus were comparable in both countries. The temporal and geographic clustering of cases of C. novyi and anthrax into outbreaks suggests possible contamination of specific heroin batches; in contrast, the more sporadic nature of tetanus and botulism cases suggests that these spores might more commonly exist in the drug supply or local environment although at varying levels. PWID should be advised about treatment programs, injecting hygiene, risks, and vaccinations.
Collapse
|
18
|
Des Jarlais DC, Feelemyer JP, Modi SN, Arasteh K, Mathers BM, Degenhardt L, Hagan H. Transitions from injection-drug-use-concentrated to self-sustaining heterosexual HIV epidemics: patterns in the international data. PLoS One 2012; 7:e31227. [PMID: 22396729 PMCID: PMC3291614 DOI: 10.1371/journal.pone.0031227] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2011] [Accepted: 01/04/2012] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Injecting drug use continues to be a primary driver of HIV epidemics in many parts of the world. Many people who inject drugs (PWID) are sexually active, so it is possible that high-seroprevalence HIV epidemics among PWID may initiate self-sustaining heterosexual transmission epidemics. METHODS Fourteen countries that had experienced high seroprevalence (<20%) HIV epidemics among PWID and had reliable data for injection drug use (IDU) and heterosexual cases of HIV or AIDS were identified. Graphs of newly reported HIV or AIDS cases among PWID and heterosexuals were constructed to identify temporal relationships between the two types of epidemics. The year in which newly reported cases among heterosexuals surpassed newly reported cases among PWID, aspects of the epidemic curves, and epidemic case histories were analyzed to assess whether it was "plausible" or "highly unlikely" that the HIV epidemic among PWID might have initiated the heterosexual epidemic in each country. RESULTS Transitions have occurred in 11 of the 14 countries. Two types of temporal relationships between IDU and heterosexual HIV epidemics were identified, rapid high incidence transitions vs. delayed, low incidence transitions. In six countries it appears "plausible" that the IDU epidemic initiated a heterosexual epidemic, and in five countries it appears "highly unlikely" that the IDU epidemic initiated a heterosexual epidemic. A rapid decline in incidence among PWID after the peak year of new cases and national income were the best predictors of the "highly unlikely" initiation of a heterosexual epidemic. DISCUSSION Transitions from IDU concentrated epidemics to heterosexual epidemics are common in countries with high seroprevalence among PWID though there are distinct types of transitions. Interventions to immediately reduce HIV incidence among PWID may reduce the likelihood that an IDU epidemic may initiate a heterosexual epidemic.
Collapse
Affiliation(s)
- Don C Des Jarlais
- The Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, New York, New York, United States of America.
| | | | | | | | | | | | | |
Collapse
|
19
|
Hope V, Parry JV, Marongui A, Ncube F. Hepatitis C infection among recent initiates to injecting in England 2000-2008: Is a national hepatitis C action plan making a difference? J Viral Hepat 2012; 19:55-64. [PMID: 22187945 DOI: 10.1111/j.1365-2893.2010.01415.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Abstract
Around 80% of hepatitis C virus (HCV) infections in England are among injecting drug users (IDUs). The HCV Action Plan launched in 2004 includes targets to reduce HCV prevalence in recent initiates (those starting injecting in the preceding 3 years), and to increase HCV voluntary confidential testing (VCT). The Action Plan's impact is examined using surveillance data from recent initiates participating in an annual survey of IDUs in contact with specialist services across England, 2000-2008. Participants provided an oral fluid sample (tested for anti-HCV) and completed a short questionnaire (including HCV VCT and result of last test). Overall, anti-HCV prevalence among the recent initiates was 18% (619/3463); in 2004, it was 20% (59/291), other than being lower in 2000 [11%, 73/672, adjusted odds ratio (AOR) = 0.63 95%CI 0.42-0.93] there was no change over time. Prevalence increased with age; was higher among those ever imprisoned, using a needle exchange, and having a HCV VCT; and varied by region. Overall, 42% (1460) had ever had a HCV VCT; in 2004 uptake was 45% (130/291) having increased from 26% (175/672, AOR = 0.57 95%CI 0.42-0.77) in 2000, and it rose to 62% (197/320, AOR = 2.12 95%CI 1.50-2.99) in 2008. The proportion of anti-HCV-positive IDUs aware of their infection was higher in 2006-2008 than in earlier years. The HCV Action Plan has probably helped increase recent initiates' uptake of HCV VCT and the proportion of those diagnosed with HCV infection. However, its impact on HCV transmission is unclear. There is a need to reinvigorate, and improve coverage of, interventions to prevent HCV transmission.
Collapse
Affiliation(s)
- V Hope
- Centre for Infections, Health Protection Agency, London, UK
| | | | | | | |
Collapse
|
20
|
Bevan G. Problem drug use the public health imperative: what some of the literature says. SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY 2009; 4:21. [PMID: 20015369 PMCID: PMC2805619 DOI: 10.1186/1747-597x-4-21] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 06/26/2009] [Accepted: 12/16/2009] [Indexed: 12/21/2022]
Abstract
Background With more than 200,000 problem drug users is contact with structured treatment services in England the public health imperative behind drug treatment is great. Problem drug use for many is a chronic and relapsing condition, where "cure" is often neither a reasonable or appropriate expectation and it can further be argued that in these circumstances problem drug use is no different from any number of chronic and enduring health conditions that are managed in the health care system and therefore should be conceptualised as such. Discussion A public health approach to drug treatment emphasises the need for drug users in or accessing treatment, to reduce their harmful drug use, reduce drug use related risks such as sepsis and overdose and stay alive for longer. However a public health perspective in relation to problem drug use isn't always either apparent or readily understood and to that end there is still a significant need to continue the arguments and debate that treatment and interventions for problem and dependent drug users need to extend beyond an individualistic approach. For the purposes of discussion in this article public and population health will be used interchangeably. Summary A recognition and acceptance that a public and population health approach to the management of problem drug users is sound public health policy also then requires a long term commitment in terms of staffing and resources where service delivery mirrors that of chronic condition management.
Collapse
Affiliation(s)
- Gez Bevan
- University of Sunderland, Faculty of Applied Sciences, Chester Rd, Sunderland, SR1 3SD, UK.
| |
Collapse
|
21
|
Camoni L, Regine V, Colucci A, Conte ID, Chiriotto M, Vullo V, Sebastiani M, Cordier L, Beretta R, Fiore JR, Tateo M, Affronti M, Cassarà G, Suligoi B. Changes in at-risk behavior for HIV infection among HIV-positive persons in Italy. AIDS Patient Care STDS 2009; 23:853-8. [PMID: 19803694 DOI: 10.1089/apc.2009.0036] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Many HIV-positive persons reportedly continue to engage in at-risk behavior. We compared the sexual and drug-using practices of HIV-positive persons before and after the diagnosis of HIV infection to determine whether their behavior had changed. To this end, in 2006, we conducted a cross-sectional study involving clinical centers in five Italian cities. Each center was asked to enroll 100 persons aged 18 years or older who had a diagnosis of HIV infection that dated back at least 2 years. Data were collected with a specifically designed questionnaire, administered during a structured interview. The McNemar chi2 test was used to compare the data before and after the diagnosis. A total of 497 persons participated (65.5% males; median age of 40 years; age range, 34-45 years). The most common exposure categories were: heterosexual contact (43.4%), homosexual contact (27.2%), and injecting drug use (20.6%). Although the percentage of drug users significantly decreased after diagnosis, 32.4% of injectors continued to use drugs, and approximately half of them exchanged syringes. Regarding sexual behavior, after diagnosis there was a significant decrease in the number of sexual partners and in stable relationships and an increase in condom use, both for persons with stable partners and those with occasional partners, although the percentage varied according to the specific sexual practice. These results indicate that though at-risk behavior seems to decrease after the diagnosis of HIV infection, seropositive persons continue to engage in at-risk practices, indicating the need for interventions specifically geared toward HIV-positive persons.
Collapse
Affiliation(s)
- Laura Camoni
- Epidemiology Unit, Department of Infectious Diseases, National Health Institute, Rome, Italy
| | - Vincenza Regine
- Epidemiology Unit, Department of Infectious Diseases, National Health Institute, Rome, Italy
| | - Anna Colucci
- Epidemiology Unit, Department of Infectious Diseases, National Health Institute, Rome, Italy
| | - Ivano Dal Conte
- Infectious Diseases Department, Amedeo di Savoia Hospital and University of Turin, Turin, Italy
| | - Monica Chiriotto
- Infectious Diseases Department, Amedeo di Savoia Hospital and University of Turin, Turin, Italy
| | - Vincenzo Vullo
- Department of Infectious and Tropical Diseases, “La Sapienza” University, Rome, Italy
| | - Marina Sebastiani
- Department of Infectious and Tropical Diseases, “La Sapienza” University, Rome, Italy
| | - Laura Cordier
- Division of Infectious Diseases, “L. Sacco” Hospital, Milan, Italy
| | | | - Josè Ramon Fiore
- Department of Infectious Diseases, Foggia University, Foggia, Italy
| | | | - Mario Affronti
- Ambulatorio di Medicina dei Viaggi, del Turismo e delle Migrazioni, Palermo University, Palermo, Italy
| | - Giuseppina Cassarà
- Ambulatorio di Medicina dei Viaggi, del Turismo e delle Migrazioni, Palermo University, Palermo, Italy
| | - Barbara Suligoi
- Epidemiology Unit, Department of Infectious Diseases, National Health Institute, Rome, Italy
| |
Collapse
|
22
|
Sweeting MJ, Hope VD, Hickman M, Parry JV, Ncube F, Ramsay ME, De Angelis D. Hepatitis C infection among injecting drug users in England and Wales (1992-2006): there and back again? Am J Epidemiol 2009; 170:352-60. [PMID: 19546152 PMCID: PMC2714950 DOI: 10.1093/aje/kwp141] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Changes in hepatitis C virus (HCV) prevalence from 1992 to 2006 were examined by using 24,311 records from unlinked anonymous surveillance of injecting drug users in England and Wales. Bayesian logistic regression was used to estimate annual prevalence, accounting for changing recruitment patterns (age, gender, injecting duration, geographic region, interactions) and the sensitivity and specificity of different oral fluid testing devices. After controlling for these differences, the authors found that the adjusted HCV prevalence decreased from 70% (95% credible interval: 62, 78) in 1992 to 47% (95% credible interval: 43, 51) in 1998 before rising again to 53% (95% credible interval: 48, 58) in 2006. Women injecting drug users had a higher HCV risk than did men (odds ratio = 1.50, 95% credible interval: 1.31, 1.73). Two regions (London and North West) had a markedly higher HCV prevalence than did the rest of England and Wales. Among individuals who had injected for less than 1 year, the adjusted HCV prevalence in 2006 was higher than that in 1992 (28% vs. 19%, respectively). HCV infection can be prevented. The public health challenge in England and Wales is to increase action in order to regain a downward trend in HCV risk and the benefit that has been lost since 1998.
Collapse
Affiliation(s)
- Michael J Sweeting
- Medical Research Council Biostatistics Unit, Institute of Public Health, Robinson Way, Cambridge, UK.
| | | | | | | | | | | | | |
Collapse
|
23
|
Camoni L, Regine V, Salfa MC, Nicoletti G, Canuzzi P, Magliocchetti N, Rezza G, Suligoi B, The SerT Study Group, Camoni L, Regine V, Salfa MC, Nicoletti G, Canuzzi P, Magliocchetti N, Rezza G, Suligoi B, The SerT Study Group. Prevalence and correlates of infection with human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among drug users in Italy: A cross-sectional study. ACTA ACUST UNITED AC 2009; 41:520-3. [DOI: 10.1080/00365540902946528] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
24
|
Hickman M, Hope V, Coleman B, Parry J, Telfer M, Twigger J, Irish C, Macleod J, Annett H. Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. J Public Health (Oxf) 2009; 31:374-82. [PMID: 19596666 DOI: 10.1093/pubmed/fdp067] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND We report on an exercise to estimate the prevalence of injecting drug use (IDU) and associated harms in a single primary care trust. METHODS Covariate capture-recapture methods to estimate (i) IDU prevalence; respondent driven sampling to measure (ii) prevalence of HCV and HIV and record linkage to measure (iii) mortality risk. RESULTS (i) The overall estimated number of IDU was 5540 (95% confidence interval, CI: 4710-6780) for all cases and 3280 (95% CI: 1940-4610) for cases matched to primary care register, i.e. a prevalence of 2.2 and 1.3% aged 15-54, respectively. (ii) The prevalence of HCV, hepatitis B and HIV was: 53, 32 and 0.7%. Over 70% of IDU in Bristol reported having at least one vaccination for HBV; more than half of those who were HCV positive were undiagnosed. (iii) The all-cause and overdose mortality rates for IDU were 0.75 and 0.4% respectively; and the standardized mortality ratio was 7.8 (95% CI: 5.4-10.8). CONCLUSION Locally specific and useful intelligence on injecting and its health consequence can be generated to inform local public health action, and may contribute information to validate national prevalence estimates.
Collapse
Affiliation(s)
- Mathew Hickman
- Department of Social Medicine, University of Bristol, Canynge Hall, Bristol, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Cauldbeck MB, O'Connor C, O'Connor MB, Saunders JA, Rao B, Mallesh VG, Praveen Kumar NK, Mamtha G, McGoldrick C, Laing RBS, Satish KS. Adherence to anti-retroviral therapy among HIV patients in Bangalore, India. AIDS Res Ther 2009; 6:7. [PMID: 19400929 PMCID: PMC2681471 DOI: 10.1186/1742-6405-6-7] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2008] [Accepted: 04/28/2009] [Indexed: 11/10/2022] Open
Abstract
INTRODUCTION Human Immunodeficiency Virus (HIV) has an estimated prevalence of 0.9% in India (5.2 million). Anti-retroviral drugs (ARV) are the treatments of choice and non-adherence is an important factor in treatment failure and development of resistance, as well as being a powerful predictor of survival. This study assesses adherence to ARV in HIV positive patients in Bangalore, India, a country where only 10% of those who need therapy are receiving it. METHODS A cross-sectional anonymous questionnaire survey of 60 HIV antibody positive patients was carried out with patients attending HIV outpatient services at two centres: The Chest and Maternity Centre, Rajajinagar, and Wockhardt Hospital and Heart Institute, Bangalore. Consent was obtained. Translation was done by a translator and doctors where required. Data was analysed using SPSS statistical analysis. RESULTS A response rate of 88% (53/60) was achieved. The mean patient age was 39.98 years, with 50% aged 30-40, and 73.6% of participants being male. Mean family size was 4.8 (1-13). 21% lived less than 50 kms and 21% greater than 400 kms from clinic.60% reported they were fully adherent. Adherence was statistically significantly linked to regular follow-up attendance (70.5%, p = 0.002). No other results were statistically significant but trends were found. "100% adherence" trends were seen in older patients, male gender, those from larger families, those who had a previous AIDS defining illness, those taking fewer tablets, and without food restrictions. Commonest side-effects causing non-adherence were metabolic reasons (66%) and GI symptoms (50%). No trends were seen for education level, family income, distance travelled to clinic, time since diagnosis, or time on ART. CONCLUSION Regular attendance for follow up was statistically significant for 100% lifetime adherence. Positive trends were seen in those in larger families, older, those who had AIDS defining illness, simple regimes, and without side-effects. Education, income, distance travelled and length of time diagnosed or treated had no effect on adherence.
Collapse
Affiliation(s)
- Mary B Cauldbeck
- The School of Medicine, University of Aberdeen, Aberdeen, Scotland, UK
| | - Catherine O'Connor
- GU/STD Clinics, Department of GU/STD Medicine, Mid-Western Regional Hospital, Limerick, Ireland
| | - Mortimer B O'Connor
- Department of Medicine, South Infirmary – Victoria University Hospital, Cork, Ireland
- The School of Medicine, University College Cork, Cork, Ireland
| | - Jean A Saunders
- Department of Mathematics and Statistics, University of Limerick, Limerick, Ireland
| | - Bhimasena Rao
- Department of Respiratory and HIV Medicine, Rajajinagar and Wockhardt Hospital and Heart Institute, Bangalore, India
| | - V G Mallesh
- Department of Respiratory and HIV Medicine, Rajajinagar and Wockhardt Hospital and Heart Institute, Bangalore, India
| | | | - Gurushanthappa Mamtha
- Department of Respiratory and HIV Medicine, Rajajinagar and Wockhardt Hospital and Heart Institute, Bangalore, India
| | - Claire McGoldrick
- Infection Unit, Department of Infectious Diseases, Aberdeen Royal Infirmary, Aberdeen, Scotland, UK
| | - Robert BS Laing
- Infection Unit, Department of Infectious Diseases, Aberdeen Royal Infirmary, Aberdeen, Scotland, UK
| | - Kadappa Shivappa Satish
- Department of Respiratory and HIV Medicine, Rajajinagar and Wockhardt Hospital and Heart Institute, Bangalore, India
| |
Collapse
|
26
|
Platt L, Sutton AJ, Vickerman P, Koshkina E, Maximova S, Latishevskaya N, Hickman M, Bonell C, Parry J, Rhodes T. Measuring risk of HIV and HCV among injecting drug users in the Russian Federation. Eur J Public Health 2009; 19:428-33. [DOI: 10.1093/eurpub/ckp041] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Craine N, Parry J, O'Toole J, D'Arcy S, Lyons M. Improving blood-borne viral diagnosis; clinical audit of the uptake of dried blood spot testing offered by a substance misuse service. J Viral Hepat 2009; 16:219-22. [PMID: 19175879 DOI: 10.1111/j.1365-2893.2008.01061.x] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Abstract
The diagnosis of blood-borne viral infection amongst drug injectors in Wales is limited by a poor uptake of diagnostic testing; recent research suggests that dried blood spot (DBS) sample collection, rather than venepuncture, may improve diagnostic rates. We carried out an audit of the uptake of DBS testing for hepatitis C, hepatitis B and HIV amongst drug injectors attending a substance misuse service (SMS) in the first year of DBS testing being routinely offered to clients (1 May 2007 to 30 April 2008) and compared the uptake to venepuncture testing of SMS clients in the previous year. Uptake of DBS testing for hepatitis C, hepatitis B and HIV was almost six times greater than the uptake of venepuncture testing amongst clients of the SMS in the previous year. The data are consistent with the hypothesis that DBS testing can increase the uptake of blood-borne viral testing amongst current and ex-drug injectors. We accept that part of the almost sixfold increase in diagnostic testing observed in the first year of DBS testing may be due to an increase in awareness amongst drug injectors of testing opportunities and a prioritization of testing by the SMS. Nonetheless the dramatic increase in uptake demonstrates that DBS testing is acceptable to drug injectors and should be subject to more rigorous trials to evaluate its potential impact on diagnosis.
Collapse
Affiliation(s)
- N Craine
- National Public Health Service for Wales, Ysbyty Gwynedd, Bangor, Wales, UK.
| | | | | | | | | |
Collapse
|
28
|
Sutton AJ, Hope VD, Mathei C, Mravcik V, Sebakova H, Vallejo F, Suligoi B, Brugal MT, Ncube F, Wiessing L, Kretzschmar M. A comparison between the force of infection estimates for blood-borne viruses in injecting drug user populations across the European Union: a modelling study. J Viral Hepat 2008; 15:809-16. [PMID: 18761605 DOI: 10.1111/j.1365-2893.2008.01041.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
A number of studies have been conducted in injecting drug user (IDU) populations in Europe, in which the prevalence of human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) was measured together with demographic and epidemiological information such as age and the age at first injection. A measure of the risk of becoming infected is the force of infection (FOI), defined as the per capita rate at which susceptible individuals acquire infection. The objective of this study was to estimate the FOI and its heterogeneity for HBV, HCV and HIV (where available) for IDU populations in a number of countries in Europe. Data were obtained from five countries: Belgium, the United Kingdom, Spain and Italy, and the Czech Republic, which provided two data sets. The model describes the prevalence of infection as a function of the FOI that may vary over time or duration of IDU. In addition to this, if two or more infections were being considered then a parameter describing the potential heterogeneity of the FOI within the IDU population was also estimated. The results here add to the growing evidence that new initiates to injecting are at an increased risk of blood-borne viral infection compared with more experienced IDUs. In addition, there is evidence of individual heterogeneity of FOI estimates within the overall IDU populations. This suggests that different proportions of individuals in each population are at increased risk of infection compared with the rest of the population. Future interventions should identify and target these individuals. Moreover, changes over time in individual heterogeneity estimates of IDU populations may provide an indicator for measuring intervention impacts.
Collapse
Affiliation(s)
- A J Sutton
- Ecology and Epidemiology Group, Department of Biological Sciences, University of Warwick, Coventry, UK.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Representativeness of Injecting Drug Users Who Participate in HIV Surveillance. J Acquir Immune Defic Syndr 2008; 47:632-8. [DOI: 10.1097/qai.0b013e31816a1d68] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Davis M. The 'loss of community' and other problems for sexual citizenship in recent HIV prevention. SOCIOLOGY OF HEALTH & ILLNESS 2008; 30:182-196. [PMID: 18290931 DOI: 10.1111/j.1467-9566.2007.01050.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Increases in reported unsafe sex among gay men have been explained as resistance to HIV prevention, or most recently, with the idea that a hyper-individualization of sexual action contributes to the loss of sexual community. This turning in HIV prevention has come to focus on the sexual action of gay men with HIV through the frames of: sexual transgression, sometimes called 'barebacking'; and altruism. Adopting the perspective of sexual citizenship in connection with qualitative interviews, this paper considers how gay men with HIV account for their sexual practice in light of the dual discourse of transgression/altruism. The paper will argue that gay men with HIV are deeply aware of what transgression/altruism implies for their identities and sexual relations, indicating the continued salience of community for sexual practice. Further, in the circumstances of blaming in relation to the moral labour of safer sex, gay men with HIV are trying to work out a co-operative practice for HIV prevention based on self-care, a moderated altruism and the voluntary action of sexual partners.
Collapse
Affiliation(s)
- Mark Davis
- School of Political and Social Inquiry, Monash University, Melbourne, Australia.
| |
Collapse
|
31
|
Hickman M, Hope V, Brady T, Madden P, Jones S, Honor S, Holloway G, Ncube F, Parry J. Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. J Viral Hepat 2007; 14:645-52. [PMID: 17697017 DOI: 10.1111/j.1365-2893.2007.00855.x] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
We sought to corroborate geographical differences in hepatitis C virus (HCV) prevalence and assess whether these can be explained by differences in injecting risk behaviour. A community recruited interview survey of 1058 injecting drug users (IDU) - including a blood spot specimen for antibody testing - was undertaken in seven cities in England. HCV prevalence varied from 27% to 74% across sites (chi(2)(6) = 115.3, P < 0.001). There was a significant variation in crack-injection, prison history, injecting frequency, homelessness, groin injecting, syringe reuse and sharing between the sites. Adjustment for clustering by site and other covariates attenuated the odds ratios (OR) for most variables: e.g. crack injection changed from an unadjusted OR of >2 to an adjusted OR of 1.4 (95% CI 0.9-2.0). Remaining significant covariates included: homelessness (OR 2.2; 1.4-3.6); ever imprisonment (OR 1.7; 1.2-2.5); syringe sharing >18 months ago (OR 2.0; 1.3-3.0); injecting duration and age. Introducing site as a second level variable did not reach significance (P = 0.10). HCV prevalence among IDU reporting 'never sharing' was 48%. Geographical variation in HCV prevalence remains poorly explained, but should be the key focus of our surveillance effort. Measures of sharing and their interpretation require greater scrutiny.
Collapse
Affiliation(s)
- M Hickman
- Social Medicine, University of Bristol, Bristol, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Judd A, Hickman M, Hope VD, Sutton AJ, Stimson GV, Ramsay ME, Gill ON, Parry JV. Twenty years of selective hepatitis B vaccination: is hepatitis B declining among injecting drug users in England and Wales? J Viral Hepat 2007; 14:584-91. [PMID: 17650293 DOI: 10.1111/j.1365-2893.2007.00844.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Injection drug use is a common route of infection for the hepatitis B virus (HBV) in the UK. The aim of this study was to establish the prevalence and force of infection for HBV among injecting drug users (IDUs) recruited from multiple community and drug agency settings in England and Wales between 1990 and 2004. Cross-sectional studies of IDUs in and out of contact with drug agencies were conducted throughout the 15-year period. Oral fluid samples were tested for antibodies to the hepatitis B core antigen (anti-HBc). Logistic regression was used to investigate associations between risk factors and anti-HBc positivity and force of infection models were explored. In total, 2527 injectors were recruited from community settings, and 29 386 from drug agencies. Anti-HBc prevalence was 31% (95% CI 30.7-31.8%). It declined in the early 1990s from around 50% in 1992 to 25% in 1999, after which it increased slightly. It was also higher in those who had injected for longer, older IDUs, those recruited in London and North West England, and those reporting having a previous voluntary confidential HIV test. The force of infection models suggested that the incidence of infection increased in 1999-2004 compared with 1993-1998, and was higher in new injectors compared with those injecting for > or =1 year. In conclusion, findings suggest ongoing HBV transmission in recent years despite an overall decline in prevalence in the early and mid-1990s, and highlight the importance of targeting vaccination programmes at new IDUs who have high incidence rates of infection.
Collapse
Affiliation(s)
- A Judd
- MRC Clinical Trials Unit, London, UK.
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Hough N. Communicable Disease and Health Protection Quarterly Review: October to December 2006. From the Health Protection Agency, Centre for Infections. J Public Health (Oxf) 2007; 29:203-7. [PMID: 17556537 DOI: 10.1093/pubmed/fdm029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
Vickerman P, Hickman M, Judd A. Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study. Int J Epidemiol 2007; 36:396-405. [PMID: 17218325 DOI: 10.1093/ije/dyl276] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
BACKGROUND Hepatitis C virus (HCV) prevalence and incidence among injecting drug users (IDUs) has increased in London and rest of UK. To inform public health action, mathematical modelling is used to explore the possible impact of strategies to decrease syringe sharing. METHODS A mathematical model was developed to simulate HCV transmission amongst IDUs in London. Because of parameter uncertainty, numerical search algorithms were used to obtain different model fits to HCV seroprevalence data from London for 2002-03. These simulations were used to explore the likely impact of HCV prevention activities that reduce syringe sharing amongst all IDUs, IDUs that have injected for greater than one year, or IDUs with lower or higher frequencies of syringe sharing. RESULTS Key differences between model fits centred on how they simulated the high HCV incidence amongst new injectors, either through assuming increased HCV infectivity during acute infection, a large sub-group of high frequency syringe sharers, or increased sharing among new IDUs. Despite parameter uncertainty, the model projections suggest that modest reductions in syringe sharing frequency (<25%) will reduce the HCV seroprevalence in newly initiated IDUs (injecting less than four years) but much larger and sustained reductions (>50%) are required to reduce the HCV seroprevalence in long-term IDUs (injecting more than 8 years). Critically the model also suggested that large reductions in HCV seroprevalence will be achieved only if interventions target all IDUs and reach IDUs within 12 months of injecting. DISCUSSION Public health interventions must reduce syringe sharing amongst all IDUs, including newly initiated IDUs, and be sustained for many years to reduce HCV infection. More accurate data on key behavioural (sharing frequency) and biological (percentage of infected IDUs that clear infection) parameters is required to improve model projections.
Collapse
Affiliation(s)
- P Vickerman
- HIVTools Research Group, London School of Hygiene and Tropical Medicine, London, UK.
| | | | | |
Collapse
|
35
|
Mehta SH, Galai N, Astemborski J, Celentano DD, Strathdee SA, Vlahov D, Nelson KE. HIV incidence among injection drug users in Baltimore, Maryland (1988-2004). J Acquir Immune Defic Syndr 2006; 43:368-72. [PMID: 16980912 DOI: 10.1097/01.qai.0000243050.27580.1a] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND We examined recent trends (1999-2004) in HIV incidence among a cohort of injection drug users (IDUs) followed since 1988 in Baltimore, Maryland. METHODS One thousand eighty-three HIV-seronegative individuals with a history of injection drug use were recruited between 1988 and 1998 and returned for >or=1 semiannual follow-up visit, where they underwent HIV antibody testing and interviews eliciting risk behaviors. Person-time methods were used to calculate HIV incidence rates per 100 person-years (PYs). RESULTS Over 14,770 PYs, 304 individuals seroconverted to HIV (2.06 per 100 PYs). Annual incidence declined from 4.57 in 1988 to 0.53 per 100 PYs in 2004. Similarly, among individuals actively injecting drugs, incidence steadily declined from 5.43 in 1988 to 0 in 2004, with the exception of 2003, when an incidence of 2.59 per 100 PYs was observed. Reported sexual risk behaviors and drug injection declined from 1988 through 2004, but among those actively injecting, reported needle sharing declined from 1988 through 1998 and then increased from 30% in 1998 to nearly 40% in 2003 through 2004. CONCLUSIONS Long-term declines in HIV incidence among IDUs are consistent with other reports; however, in 2003, we observed an unexpected increase in seroconversion that seems to be related to needle sharing. Although additional follow-up is needed to identify trends, these data indicate the need to reinforce HIV prevention efforts and to continue surveillance of drug users' behaviors.
Collapse
Affiliation(s)
- Shruti H Mehta
- Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21202, USA.
| | | | | | | | | | | | | |
Collapse
|
36
|
Vickerman P, Hickman M, Rhodes T, Watts C. Model Projections on the Required Coverage of Syringe Distribution to Prevent HIV Epidemics Among Injecting Drug Users. J Acquir Immune Defic Syndr 2006; 42:355-61. [PMID: 16645549 DOI: 10.1097/01.qai.0000219788.73539.47] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Although syringe distribution is effective in preventing HIV transmission among injecting drug users (IDUs), there is little evidence on the required coverage to substantially reduce HIV transmission. METHODS A mathematical model is developed to explore the relationship between the endemic HIV prevalence among IDUs and the coverage of syringe distribution. Data from IDU populations in the United Kingdom and Belarus are used to explore the implications of increasing coverage and the effect of changes in other behaviors. RESULTS Projections suggest that there is a coverage threshold, which, if reached, could lead to substantial decreases in HIV prevalence. The threshold largely depends on the frequency that IDUs inject and (safely) reuse their syringes, and corresponds to less than 4 syringe-sharing events per IDU per month. Other factors, such as the injecting cessation rate and efficacy of syringe cleaning, only have substantial impact near threshold coverage levels. CONCLUSIONS Our results support a policy of increasing the coverage of syringe distribution but highlight the difficulty in producing a universal coverage target. Great public health benefit could be conferred by encouraging the safe reuse of an IDU's own syringes and small stable injecting groups. Policies that discourage this will negate the impact of syringe distribution interventions.
Collapse
Affiliation(s)
- Peter Vickerman
- HIVTools Research Group, London School of Hygiene and Tropical Medicine, London, UK.
| | | | | | | |
Collapse
|